Chemistry:Nibrozetone
From HandWiki
Nibrozetone is an investigational new drug that is being evaluated by EpicentRx for the treatment of oral mucositis in head and neck cancer patients. It is a small molecule that combines direct inhibition of the NLRP3 inflammasome, induction of NRF2, and release of nitric oxide under hypoxic conditions.[1][2] It has received Fast Track designation from the FDA for severe oral mucositis in head and neck cancer patients.[3]
References
- ↑ "RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist". Frontiers in Oncology 13. 2023. doi:10.3389/fonc.2023.1204143. PMID 37313460.
- ↑ "A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation". Drugs 83 (5): 389–402. April 2023. doi:10.1007/s40265-023-01838-z. PMID 36920652.
- ↑ "FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer" (in en). 30 March 2023. https://www.onclive.com/view/fda-grants-fast-track-designation-to-rrx-001-for-severe-oral-mucositis-in-head-and-neck-cancer#.
 |  |
